NCT05141383Completed
Comparative Study of Diagnostic and Prognosis Biomarkers of Prostate Cancer in Liquid Biopsy (HOPE)
Comparative Study of Diagnostic and Prognosis Biomarkers of Prostate Cancer in Liquid Biopsy
Source: ClinicalTrials.gov · Last updated 8 Sept 2025
Brief summary (registry, in English)
Constitution of a biological collection within the framework of the establishment of a diagnostic, prognostic and active surveillance test for prostate cancer from long non-coding RNA biomarkers, in 3 cohorts of patients, with cancer of the prostate, with suspected cancer without biopsy confirmation or with prostatic hyperplasia and healthy donors. This biological collection will also be used as a support for further researches on the identification of biomarkers and genetic markers to improve the prognosis and diagnostic management of patients with prostate pathologies.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 80 (actual)
- First submitted
- 19 Nov 2021
- Start date
- 4 May 2022
- Primary completion date
- 3 Sept 2024
- Lead sponsor
- Institut Curie
- Diseases
- Prostate cancer
- NCT number
- NCT05141383
What you commit to
- Study type: Interventional
- Participants enrolled: 80
- From 4 May 2022 to the primary completion date, 3 Sept 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- 1 / Participants who refused to participate in the biological collection 2) Persons deprived of their liberty or under guardianship. 3) Inability to undergo medical monitoring of the trial for geographical, social or psychological reasons.
Who the study is looking for
- Concerning patients:
- / Patient with suspected prostate cancer or prostatic hyperplasia with a PSA level ≥ 4 ng / ml
- / Patient diagnosed by prostate MRI in the course of treatment
- / No infectious episode in the week before the visit (in particular no urinary tract infection) documented by dipstick and absence of fever
- / Information of the patient and signature of informed consent or his legal representative.
- / Participant affiliated to a social security scheme
- Regarding healthy volunteers:
- / Male from 50 to 70 years old
- / PSA level \< 4 ng / mL
- / No infectious episode in the week before the visit (in particular no urinary tract infection), documented by dipstick and the absence of fever
- / Absence of cancer and history of haematological pathologies \< 5 years (in particular leukemia, lymphoma).
- / Patient information and signature of consent
Age in the registry: 50 years to 70 years · Sex: Male · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institut Curie Coordinator of this site? Confirm its status | Paris | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.